Publication:
Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years

Simple item page
dc.contributor.authorMamede, Lúcia
dc.contributor.authorCantenys, Roser
dc.contributor.authorVan Coillie, Samya
dc.contributor.authorPrévot, Johan
dc.contributor.authorSánchez, Silvia
dc.contributor.authorPoli Harlowe, María Cecilia
dc.contributor.authorBarasa, Anne
dc.contributor.authorSchuller, Björn
dc.contributor.authorHendel, Ayal
dc.contributor.authorGarcelon, Nicolas
dc.contributor.authorBoersma, Cornelis
dc.contributor.authorLee, Pamela
dc.contributor.authorBooth, Claire
dc.contributor.authorNotarangelo, Luigi
dc.contributor.authorDrabwell, Jose
dc.contributor.authorRider, Nicholas
dc.contributor.authorStaal, Frank
dc.contributor.authorO Burns, Siobhan
dc.contributor.authorVan Hagen, Martin
dc.contributor.authorPergent, Martine
dc.contributor.authorRivière, Jacques
dc.contributor.authorMahlaoui, Nizar
dc.date.accessioned2026-08-26T16:17:45Z
dc.date.available2026-08-26T16:17:45Z
dc.date.issued2025
dc.description.abstractIntroduction: The International Patient Organisation for Primary Immunodeficiencies (IPOPI) held its third edition of the Global Multi-Stakeholders' Summit, gathering key primary immunodeficiencies (PID) stakeholders and experts to discuss and foment global collaboration. Methods: This edition focused on the impact of genomic medicine in PID treatment, the role of digital health, including artificial intelligence, in PID care, and how to anticipate and minimise risks to ensure optimal patient access to care. Results: These discussions aimed to examine current hurdles and brainstorm feasible solutions and priorities for the PID community in these areas in the next ten years. Discussion: These discussions led to recommendations for comprehensive approaches to care and access to treatment for PID patients, suggesting actions that will bring the community closer to treatments based on real-world evidence and adjusted to patient's needs. To accomplish this, collaboration between academia, industry, regulatory authorities, and patients is crucial.
dc.description.versionVersión Publicada
dc.identifier.citationMamede L, Sabà RC, Van Coillie S, Prévot J, Sánchez-Ramón S, Poli C, Barasa A, Schuller BW, Hendel A, Garcelon N, Boersma C, Lee P, Booth C, Notarangelo LD, Drabwell J, Rider NL, Staal FJT, Burns SO, Van Hagen M, Pergent M, Rivière JG, Mahlaoui N. Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years. Front Immunol. 2025 Jun 17;16:1596971. doi: 10.3389/fimmu.2025.1596971.
dc.identifier.doihttps://doi.org/10.3389/fimmu.2025.1596971
dc.identifier.urihttps://hdl.handle.net/11447/11038
dc.language.isoen
dc.subjectArtificial intelligence - AI
dc.subjectDigital health
dc.subjectGene therapy (GT)
dc.subjectImmunoglobulin replacement therapy (IGRT)
dc.subjectInborn errors of immunity (IEI)
dc.subjectPatient-reported outcome measures (PROMs)
dc.subjectPrimary immunodeficiencies (PIDs)
dc.subjectTargeted therapies
dc.titleNavigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years
dc.typeArticle
dcterms.accessRightsAcceso Abierto
dcterms.sourceFrontiers in immunology
dspace.entity.typePublication
relation.isAuthorOfPublicationbf711dbf-cd6f-4a66-97fb-64c15f664de3
relation.isAuthorOfPublication.latestForDiscoverybf711dbf-cd6f-4a66-97fb-64c15f664de3

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Navigating disruption in the PID landscae embracing opportunities and anticipating threats in the next ten years.pdf
Size:
547.32 KB
Format:
Adobe Portable Document Format
Description:
Texto Completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services